分類: ACN Newswire

上海, 2026年6月9日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552.HK）今日宣布，公司攜全球首創葡萄糖激酶激活劑（GKA）多格列艾汀（dorzagliatin，商品名：华堂宁（R），香港地區商品名：華領片（R）, MYHOMSIS（R））的一系列研究成果亮相第86屆美國糖尿病協會（ADA）科學年會，以口頭報告+壁報展示形式，多維度呈現了公司以代謝穩態技術平台為核心，在聯合用藥協同增效、大規模上市後真實世界證據、AI精準診療和個性化診療工具等關鍵領域的突破性進展，進一步支持了多格列艾汀從源頭上修復血糖穩態的機制優勢，提示了多格列艾汀在2型糖尿病（T2D）、代謝相關脂肪性肝病（MASLD）、肥胖、青少年發病型成人糖尿病2型 (MODY2)等複雜代謝性疾病領域的用藥潛力，持續鞏固了華領醫藥在全球血糖穩態研究領域的領先地位。一、依托代謝穩態平台，拓寬泛代謝疾病治療佈局多格列艾汀以「血糖傳感器」葡萄糖激酶（GK）為核心靶點，通過修復2型糖尿病患者受損的GK功能和表達，提升T2D患者血糖調控器官的葡萄糖敏感性，實現胰腺-肝臟-腸道多器官協同調控，從而改善患者血糖穩態，為糖尿病及一系列代謝紊亂疾病提供了全新的治療範式。基於這一獨特機制，華領醫藥在本屆ADA重點公布三項聯合用藥在代謝性疾病動物模型中的研究。結果顯示，多格列艾汀與口服小分子GLP‑1受體激動劑、甲狀腺激素受體激動劑（THR-β agonist）、泛PPAR激動劑（pan-PPAR agonist）等藥物聯用後可產生協同效應，有望在降糖之外實現減重、調脂、降尿酸、改善胰島素敏感性等多重獲益。其中，華領醫藥通過口頭報告展示了多格列艾汀聯合口服小分子GLP‑1受體激動劑orforglipron的臨床前研究成果，該研究首次在動物模型中證實，GKA與口服小分子GLP‑1受體激動劑的協同作用，為穩態修復+腸促胰素激活的口服聯合方案提供機制與數據支撐。不僅如此，研究結果提示，聯合用藥有望解決臨床應用中影響GLP-1受體激動劑用藥依從性的一大常見難題--胃腸道耐受性問題。該項研究採用hGLP‑1R轉基因伴隨飲食誘導肥胖（DIO）小鼠模型，模擬人類肥胖伴2型糖尿病的病理狀態，經4周每日一次口服給藥，系統評估了單藥與聯合治療在血糖控制、胰島素分泌、體重、血脂及安全性等方面的差異。在藥物機制上，多格列艾汀可修復胰島、肝臟、腸道的GK功能，重塑血糖穩態，提升葡萄糖刺激的胰島素分泌（GSIS），促進內源性GLP‑1分泌；orforglipron則直接激活GLP-1受體，強效減重、降糖、改善血脂，但存在胃腸道不良反應風險。本次壁報展示的研究結果顯示，聯合治療在以下方面存在協同效應：- 協同強效降糖：聯合用藥組呈現協同降糖效應，降糖效果顯著優於單藥，且具有減少兩藥用量的潛力（低劑量聯用可達高劑量單藥效果）；orforglipron還可放大多格列艾汀對β細胞功能與肝臟糖代謝的改善作用。- 顯著提升β細胞功能：多格列艾汀改善DIO小鼠的β細胞功能，聯合用藥後胰島素分泌功能與敏感性呈協同增益，實現更優血糖控制與β細胞保護。- 維持減重獲益與血脂調節獲益：聯合用藥組保留orforglipron的減重效果以及對於血脂的調節獲益。- 安全性與耐受性：聯合用藥整體耐受良好，無新增不良信號；劑量節約可顯著減少噁心、嘔吐等GLP‑1類常見胃腸道反應，提升長期依從性。該研究提示，聯合用藥實現了降糖、減重、調脂三重協同，在顯著降低空腹與餐後血糖的同時，可減少GLP‑1受體激動劑的用量，降低胃腸道不良反應，有望為2型糖尿病合併肥胖患者提供更高效、更耐受，且具備差異化優勢的口服聯合方案。未來，華領醫藥還將進一步開展臨床研究，驗證聯合用藥在人群中的療效與安全性，探索最佳劑量配比與適用人群。華領醫藥還通過壁報展示了另外兩項聯合用藥研究成果：1、在飲食誘導肥胖模型小鼠實驗中，多格列艾汀與THR-β激動劑Resmetirom聯合用藥，在MASLD小鼠模型中，能夠協同改善機體代謝狀態、發揮肝臟保護作用，有效優化血糖管控、調節血脂水平、降低尿酸，减輕肝纖維化病變。此項研究結果表明，多格列艾汀與THR-β激動劑聯合治療方案，對MASLD和T2D具備良好的臨床應用潛力。2、多格列艾汀與pan-PPAR激動劑 Chiglitazar聯合使用，在MASLD合併肥胖糖尿病小鼠模型中，展現出顯著的協同代謝獲益，降糖療效優於單藥治療，同時，可以優化基礎糖代謝水平，提升葡萄糖刺激狀態下的糖分代謝效率。該聯合方案相比單藥治療可更有效改善小鼠糖耐量、降低胰島素抵抗、提升胰島素敏感性與 β 細胞功能，並升高高密度脂蛋白膽固醇水平，證實聯用方案對MASLD相關代謝紊亂具有良好調控潛力，為後續開展臨床研究、探索其在代謝及肝臟疾病領域的治療價值提供了重要臨床前支撐。上述研究共同驗證了多格列艾汀憑藉其恢復代謝穩態的核心優勢，可以與多種靶點藥物形成協同，有望持續拓寬在肥胖、MASLD等泛代謝疾病領域的治療佈局。二、大規模上市後真實世界研究支撐臨床廣泛應用本屆ADA年會上，華領醫藥同時公布了大規模上市後真實世界研究「BLOOM研究」的更多核心數據，研究聚焦多格列艾汀在常規臨床場景中的應用，旨在評估多格列艾汀在各類不同臨床特徵的廣泛2型糖尿病患者中使用的長期安全性與療效。BLOOM研究覆蓋中國80家臨床中心，共納入2024例2型糖尿病患者（其中男性佔62%，平均年齡55.5歲，平均BMI值 25.1，糖尿病病程7.9年，基線HbA1c為7.8%），隨訪週期長達52週，全面評估了多格列艾汀在真實臨床場景中單藥或聯合其他降糖藥治療的長期安全性與有效性。研究人群高度貼近臨床實際，涵蓋不同年齡、病程、基線血糖水平、合併用藥與併發症狀態，包括老年患者、腎功能不全患者、聯用包括胰島素在內的多種降糖藥的複雜患者，結果顯示：- 52週治療期內，無藥物相關嚴重不良事件（SAE），無嚴重低血糖事件，有臨床意義的低血糖發生率低於1%，與3期臨床相比未觀察到新的不良反應；- 經52週治療，患者整體HbA1c較基線顯著下降，血糖達標率（HbA1c<7%）明顯提升；- 在基線HbA1c≥8% 的中重度血糖升高患者中，HbA1c降幅達1.11%，顯示出對血糖控制不佳患者的治療效果；- 無論單藥使用，還是與二甲雙胍、SGLT‑2抑制劑、DPP‑4抑制劑、GLP‑1受體激動劑、胰島素等聯合使用，均觀測到穩健降糖數據。BLOOM研究以大樣本、長週期、多中心真實世界數據，驗證了多格列艾汀在不同2型糖尿病人群及多種治療方案中，均展現出良好的安全性數據與穩定的血糖控制效果，為其在真實世界臨床實踐中的應用提供了有力支持此外，研究者還公布了一項真實世界研究的中期結果。該項前瞻性觀察性研究納入的真實世界255例2型糖尿病（T2D）患者，多數病程久、多藥聯用（含胰島素）治療，目前該研究中已完成6個月隨訪並有基線CGM數據的T2D共有190例，按基線TIR分為三組：TIR≤50%、50%70%，經多格列艾汀治療6個月後評估療效，研究結果如下圖所示：（各組HbA1c水平均有下降，基線TIR≤50%組降幅最高）（基線TIR不達標的兩組TIR水平均獲提升，基線TIR達標組TIR依然可以維持達標）（各組胰島β細胞功能均較前有所增加，但基線TIR≤50%組HOMA-β改善顯著）本研究的6個月中期亞組分析顯示：針對病程久、多藥聯用的真實世界T2D患者，多格列艾汀存在明確的降糖獲益；對於基線TIR差、血糖嚴重失控的患者，用藥後HbA1下降、TIR提升、胰島β細胞功能加強、胰島素抵抗改善，實現整體血糖穩態修復。該研究為複雜T2D患者臨床降糖治療新選擇提供了依據。三、AI深度賦能：構建糖尿病精準分型、預測與診療一體化新體系圍繞葡萄糖激酶（GK）核心機制，華領醫藥將人工智能（AI）、大語言模型（LLM）與臨床大數據深度融合，開發覆蓋療效預測、糖尿病緩解預測、單基因糖尿病分型、醫學智能教育等AI工具。本屆ADA會議，華領醫藥也進行了相關研究的報告- GK Charger智能知識平台：LLM驅動的交互式臨床教育系統。GK Charger是一款基於大語言模型（LLM）開發的AI賦能的醫學教育平台，整合了分子機制、藥理特性、臨床研究、指南共識與真實世界證據，可將葡萄糖激酶相關的複雜科學概念轉化為臨床及患者適用的循證內容。臨床醫生、研究者、患者和普通大衆均可隨時提問，平台可將複雜的科學概念轉化為臨床場景適用、患者易於理解的循證答案。GK Charger為精準醫學教育提供了可擴展的框架，既促進了複雜生物醫學知識的整合與傳播，也為2型糖尿病中GK靶向療法的臨床應用提供了有力支持。- 血糖控制與糖尿病緩解預測模型：個體化治療决策工具基於多格列艾汀臨床研究數據，華領醫藥構建了面向臨床醫生的療效預測模型，可預測患者接受多格列艾汀治療後的HbA1c應答率與糖尿病緩解率等關鍵指標，為2型糖尿病個體化診療與精準醫療提供了全新實用工具，未來隨著數據持續積累將進一步拓展其應用價值。- GK突變AI精準解析系統：加速MODY2精準診斷與用藥指導GK突變是導致MODY2的主要原因，華領醫藥構建了近千個GK突變數據庫，結合蛋白結構分析、蛋白進化模型、AI大語言模型等，開發了GK突變智能解析系統，可在數秒內完成突變位點定位、功能影響判斷、疾病風險評估及對多格列艾汀的應答預測，整體準確率達90%。該工具有望為MODY2快速基因診斷，指導靶向用藥提供依據，提升單基因糖尿病精準診療效率與可及性。此外，華領醫藥還公布了一項創新檢測技術，可直接用於試劑盒開發，為糖尿病短期血糖波動評估、臨床精準檢測提供更可靠、更穩定、更高效的工具。學術榮譽值得注意的是，華領醫藥研究與發現技術部高級總監馮令戈成功斬獲ADA Early Career Abstract Award（青年研究者摘要獎），獲得全球糖尿病研究領域的學界認可。該獎項旨在表彰糖尿病領域處於職業早期、具備突出學術潛力與原創貢獻的優秀研究者，是全球糖尿病學界對青年科學家的重要官方認可。基於其在多格列艾汀研發、AI輔助糖尿病精準治療算法開發等領域的長期積累和努力，此次獲獎不僅體現了華領醫藥相關研究工作的科學質量, 也進一步彰顯了華領醫藥在創新藥物研發、AI賦能糖尿病診療領域的前沿探索得到全球學術界認可，助力中國創新藥研發力量持續走向世界舞台中央。從聯合療法拓寬泛代謝疾病版圖，到真實世界證據築牢長期安全有效，再到AI 驅動精準診療全流程升級與創新檢測技術突破，華領醫藥在本次ADA年會上的系列成果，全方位、多層次、系統性印證了多格列艾汀作為全球首創GKA的機制獨特性、臨床應用廣泛性，不僅具有從「源頭」上治療2型糖尿病的潛力，也有望加速推進多格列艾汀在肥胖、MASLD、MODY2等泛代謝疾病領域，在更廣泛人群、更多代謝疾病中的臨床研究與適應症拓展。【本新聞稿所含信息源自第86屆美國糖尿病協會（ADA）科學年會公開展示的資料。本文旨在概述華領醫藥於該會議上公布的研究進展與創新成果，僅供投資者、分析師及醫療衛生專業人士瞭解科研與企業動態之用。本文件不構成任何投資建議。其中涉及的對未來預期、管綫進展或監管時間表的描述均屬前瞻性陳述，受各類風險及不確定因素影響，實際結果可能與預期存在重大差異。】關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和産品，引領全球糖尿病醫療創新。公司核心産品华堂宁（R）（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁（R）已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。2026年2月，多格列艾汀（商品名：MYHOMSIS（R），華領片（R））獲得中國香港特別行政區政府衛生署藥物辦公室的上市批准。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHANGHAI, Jun 9, 2026 - (ACN Newswire via SeaPRwire.com) - Hua Medicine ("the Company", stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name in Hong Kong: MYHOMSIS(R)), the world’s first-in-class glucokinase activator (GKA), at the 86th Scientific Sessions of the American Diabetes Association (ADA). Through oral and poster presentations that demonstrated the breadth and depth of its science, the Company showcased data from its Metabolic Homeostasis Technology Platform, spanning combination therapies, large-scale real-world outcomes, AI-powered precision medicine, and personalized care tools.Collectively, the presentations continued to demonstrate the significance of dorzagliatin’s mechanism of action – restoring glucose homeostasis at its root cause – and its therapeutic potential across a spectrum of complex metabolic diseases including Type 2 diabetes (T2D), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), obesity, and Maturity-Onset Diabetes of the Young Type 2 (MODY2).The new research findings strengthen Hua Medicine’s position as a global leader in glucose homeostasis research.I. Leveraging Metabolic Homeostasis Platform to Expand Therapeutic Landscape for Metabolic DiseasesDorzagliatin targets glucokinase (GK), the body’s fundamental glucose sensor, by repairing impaired GK function and expression in patients with Type 2 diabetes to enhance glucose sensitivity. Through coordinated multi-organ regulation across the pancreas, liver, and intestines, dorzagliatin fundamentally restores glucose homeostasis and addresses a broad spectrum of metabolic disorders.Building on this unique mechanism, Hua Medicine presented three combination therapy studies in animal models of metabolic disorder at ADA 2026. The data demonstrate that dorzagliatin acts synergistically with oral small molecule GLP-1 receptor agonists, THR-β agonists, and pan-PPAR agonists. It delivers benefits well beyond glycemic control, including weight reduction, lipid modulation, uric acid reduction, and improved insulin sensitivity.In an oral presentation, Hua Medicine reported preclinical findings evaluating dorzagliatin in combination with the oral small molecule GLP-1 receptor agonist orforglipron. In a significant scientific first, this study demonstrated synergies between a GKA and a small molecule GLP-1RA in animal models, providing a mechanistic and clinical rationale for an oral combination regime that pairs homeostasis restoration with incretin activation. Taken together, the dose-sparing effect, where low-dose combinations achieved comparable efficacy to high-dose monotherapy, addresses one of the most common barriers to GLP-1RA adherence in clinical practice: gastrointestinal tolerability.The study used diet-induced obese (DIO) human GLP-1R transgenic mice, which recapitulate human obesity-associated Type 2 diabetes. The 4-week once-daily oral treatment systematically evaluated monotherapy and combination therapy across key efficacy and safety parameters, including glycemic control, insulin secretion, body weight and lipid profiles.In this model, dorzagliatin repairs GK function across the pancreas, liver, and intestines to restore glucose homeostasis, enhance glucose-stimulated insulin secretion (GSIS), and promote endogenous GLP-1 secretion.Orforglipron directly activates GLP-1 receptors to induce robust weight loss, glycemic control, and lipid improvement; although it also carries the risk of adverse gastrointestinal (GI) events.Synergistic Glycemic Control: Combination therapy produced superior glucose-lowering effects versus monotherapy and enabled dose sparing potential, with low-dose combinations achieving efficacy comparable to high-dose monotherapy. Orforglipron amplified dorzagliatin-mediated improvements in β-cell function and hepatic glucose metabolism.Enhanced β-Cell Function: Dorzagliatin improves the β-cell function of DIO mice, and combined treatment synergistically boosted insulin secretion and sensitivity for better glycemic control and β-cell protection.Preserved Weight and Lipid Benefits: The combination fully retained orforglipron-induced weight reduction and lipid-lowering effects.Favorable Safety and Tolerability: The combination was well tolerated with no new safety signals. Dose sparing markedly reduced common GLP-1RA-related GI side effects such as nausea and vomiting, improving long-term adherence.Together, these complementary mechanisms across glycemic control, weight loss, and lipid improvement, position the potential combination as a highly effective, well-tolerated, and differentiated oral option for T2D patients with obesity. Hua Medicine plans to advance clinical studies to evaluate efficacy, safety, optimal dosing, and target patient populations most likely to benefit.Hua Medicine also presented the findings of two additional combination therapy studies in poster presentations:1.Dorzagliatin + Resmetirom (THR-β Agonist): In DIO mice with MASLD, the combination synergistically improved systemic metabolism and exerted hepatoprotective effects, optimizing glycemic control, regulating lipids, reducing uric acid, and alleviating hepatic fibrosis. This supports the clinical potential of dorzagliatin for T2D patients with MASLD.2.Dorzagliatin + Chiglitazar (Pan-PPAR Agonist): The combination of dorzagliatin and the pan-PPAR agonist chiglitazar demonstrates significant synergistic metabolic benefits in DIO mice model of MASLD. The glucose-lowering effect is superior to monotherapy. At the same time, it optimizes basal glucose metabolism and improves glucose disposal following glucose challenge. Compared with monotherapy, this combination regimen more effectively improves glucose tolerance, reduces insulin resistance, enhances insulin sensitivity and β-cell function, and elevates high-density lipoprotein cholesterol levels in mice. These findings underscore the potential of this combination to address metabolic dysregulation in MASLD and provide important preclinical support for subsequent clinical research to explore its therapeutic value in the metabolic and liver diseases.Together, these studies demonstrate that dorzagliatin’s core mechanism of restoring metabolic homeostasis operates synergistically with multiple targeted agents, supporting its therapeutic potential in obesity, MASLD, and other metabolic disorders.II. Large-Scale Post-Marketing Real-World Study (BLOOM) Validates Long-Term Efficacy and SafetyAt ADA 2026, Hua Medicine presented further key results from the BLOOM study, a large-scale post-marketing real-world investigation of dorzagliatin in routine clinical settings.BLOOM aims to evaluate the long-term safety and effectiveness of dorzagliatin in a broad, clinically diverse population of people with Type 2 diabetes. The BLOOM study enrolled 2,024 patients with Type 2 diabetes across 80 clinical centers in China (62% male; mean age 55.5 years; mean BMI 25.1 kg/m²; mean diabetes duration 7.9 years; baseline HbA1c 7.8%) with dorzagliatin treatment and follow-up lasting up to 52 weeks. It evaluated long-term safety and effectiveness of dorzagliatin as monotherapy or in combination with other anti-diabetic agents in real clinical settings, including elderly patients, people with renal impairment, and those on complex multiple-drug regimens including insulin. The study results demonstrated that:During the 52-week treatment period, no drug-related serious adverse events (SAEs) or severe hypoglycemia were reported over 52 weeks. Clinically meaningful hypoglycemia remained <1%, no new adverse events were seen compared with Phase â…¢ clinical trials.After 52 weeks, HbA1c was significantly reduced from baseline, and the proportion of patients achieving HbA1c <7% increased markedly.In patients with moderate-to-severe hyperglycemia (baseline HbA1c ≥8%), HbA1c decreased by 1.11%.Robust glycemic control was observed with dorzagliatin monotherapy and in combination with metformin, SGLT-2i, DPP-4i, GLP-1RA, and insulin.The BLOOM study’s large sample size, long 52-week duration, and multi-center real-world design provide robust evidence of dorzagliatin’s strong safety profile and consistent glycemic control across diverse T2D patients and therapeutic regimens found in real world clinical practice.Hua Medicine also presented interim findings from a real-world prospective observational study enrolling 255 patients with Type 2 diabetes who had baseline continuous glucose monitoring (CGM) data. The majority of patients had long disease duration and were already receiving multi-drug regimens including insulin. Among this population, 190 T2D patients completed the six-month follow-up. The results are shown in the figure below: (HbA1c declined across all subgroups, with the greatest reduction observed in patients whose baseline TIR ≤50%)( TIR increased in the two subgroups with suboptimal baseline TIR, while the group with baseline TIR meeting the target maintained satisfactory TIR levels.)(β-cell function improved in all groups, with a marked elevation in HOMA-β seen in the subgroup with baseline TIR ≤50%)This subgroup analysis of the 6-month interim results indicates that dorzagliatin provides meaningful efficacy in glycemic control among real-world T2D patients that are characterized by long duration of disease and high prevalence of combination therapy with multiple antidiabetic agents, including insulin. Even in patients with severely compromised baseline TIR, clinically meaningful reductions in HbA1c, improved TIR, enhanced β-cell function, and reduced insulin resistance were observed, collectively indicating the restoration of glucose homeostasis.III. Deep Integration of AI Builds an Integrated System for Precision Diabetes Classification, Prediction, and CareBy integrating artificial intelligence (AI), large language models (LLM), and clinical big data around the core GK mechanism, Hua Medicine has developed a full suite of AI tools for efficacy prediction, diabetes remission forecasting, monogenic diabetes classification, and intelligent medical education.1.GK Charger: An LLM-powered interactive medical education platform that integrates molecular mechanisms, pharmacological profiles, clinical studies, guidelines, and real-world evidence. It translates complex GK-related scientific concepts into clinically actionable and non-specialist-friendly evidence-based content for clinicians, researchers, patients, and the public, supporting scalable precision medical education and adoption of GK-targeted therapies.2.Glycemic Control and Diabetes Remission Prediction Models: Clinician-oriented predictive tools built on dorzagliatin clinical data to estimate the probability of HbA1c response and diabetes remission after treatment. These web-based applications support personalized T2D management and precision medicine, with performance expected to improve as data accumulates.3.AI-Powered GK Variant Analysis System: A precision tool for MODY2 built on a database of approximately 1,000 GK variants, combining structural analysis, evolutionary modeling, and LLMs. It delivers 90% accurate predictions of variant location, functional impact, disease association, and dorzagliatin response in seconds, accelerating genetic diagnosis and targeted medication guidance for MODY2.Hua Medicine also introduced a novel ATP-independent enzymatic cycling system for highly efficient glucose removal from biological samples without generating oxidative byproducts or depleting ATP, preserving native metabolome integrity. It enables accurate quantification of 1,5-anhydroglucitol (1,5-AG), a key marker for short-term glycemic variability, supporting reliable and high-throughput precision diabetes testing.Academic RecognitionNotably, Lingge Feng, Senior Director of Research and Discovery Technology at Hua Medicine, was awarded the ADA Early Career Abstract Award, earning recognition from the global diabetes research community. The award honors outstanding early-career investigators in the diabetes field who demonstrate exceptional academic potential and original contributions, representing an important official endorsement from the global diabetes community.With long-standing expertise in dorzagliatin development and AI-enabled precision diabetes therapeutics, this recognition not only reflects the scientific quality of Hua Medicine’s research efforts, but also underscores the growing international academic recognition of Hua Medicine’s cutting-edge work in innovative drug R&D and AI-powered diabetes care, further advancing innovative Chinese pharmaceutical research onto the world stage.From combination therapies expanding metabolic disease indications, to real-world evidence validating long-term safety and efficacy, to AI-driven precision care and breakthrough diagnostic technologies, Hua Medicine’s 2026 ADA data comprehensively validate the mechanistic uniqueness and broad clinical utility of dorzagliatin—the world’s first commercialized GKA. Beyond Type 2 diabetes, these findings are expected to accelerate clinical development and label expansion into obesity, MASLD, MODY2, and other metabolic disorders to benefit broader patient populations.This press release contains information that is in the public domain following presentation(s) at the 86th ADA Scientific Sessions. It is issued for informational purposes to shareholders, investors, analysts and healthcare professionals. Nothing in this release should be construed as investment advice. Where applicable, statements regarding future expectations, pipeline progression or regulatory timelines are forward-looking statements subject to risks and uncertainties — actual results may differ materially.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for T2D patients with with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS(R)) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestors: ir@huamedicine.comMedia: pr@huamedicine.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

KOSICE, SLOVAKIA, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - The original film by Vlado Zelezňák Jr. has achieved remarkable international success. The new Slovak-Japanese animated sci-fi film Angel & Meow celebrated its World Premiere by winning the prestigious Crystal Pine Award. The film proved its quality against an immense global competition of nearly 1,000 entries from 81 countries. This achievement is particularly notable as the film was produced as a fully independent project by the Slovak company GONG Art Company, led by Vlado Zelezňák Sr.The success took place at the 14th International Sound & Film Music Festival (ISFMF) in Varazdin, Croatia, which ranks among the world’s three most significant festivals dedicated to film music and sound. The gala ceremony was held in the magnificent historic setting of the Croatian National Theatre (HNK Varazdin).In the Company of Oscar Winners and Hollywood Stars The winners were selected by a prestigious international jury consisting of elite professionals—recipients and nominees of Oscar, Emmy, BAFTA, Grammy, and César awards. The jury president for this year was the legendary and respected actor Ciarán Hinds. Widely considered one of the most acclaimed actors of his generation, Hinds is known to audiences for global blockbusters such as Game of Thrones, Harry Potter and the Deathly Hallows, the Oscar-winning drama Belfast, and the animated phenomenon Frozen.Slovak creators stood on stage alongside the world’s absolute elite. Other award-winning personalities at this year’s festival included Hollywood actor Simon Pegg (Mission: Impossible, Star Trek), who received a Lifetime Achievement Award, and Oscar-winning sound designer James Mather (Top Gun: Maverick). The Slovak team shared the spotlight with elite sound professionals from the film Sirât, including Yasmina Praderas (Goya winner and Oscar nominee) and Laia Casanovas (European Film Award and Goya winner).Personal Moments from the Festival Stage The heart and engine of the project is Slovak producer, screenwriter, composer, and sound designer Vlado Zelezňák Jr., who accepted the award directly from the festival directors. During the gala, he experienced unforgettable personal encounters with the world’s biggest film stars."When we stood on stage after the announcement, I expressed my appreciation to the jury president, Ciarán Hinds, for his work. I was delighted that he already recognized our film—he responded immediately with a wide smile by singing the title of our project. It was a pleasant and spontaneous experience," recalls Vlado Zelezňák Jr.The meeting with Hollywood actor Simon Pegg was equally emotional. "I spoke with Simon on the day of the World Premiere, where I had the opportunity to introduce our film to him personally. When we met again on stage the next day during the awards ceremony, it was great to see that he was familiar with Angel & Meowand congratulated me with a smile again. These moments are a huge encouragement for my future work," adds the Slovak creator.The entire event was managed by the festival founders. The gala was hosted by Artistic Director Ozren K. Glaser, who publicly congratulated Vlado Zelezňák Jr. on stage, while Executive Director Marijana Glaser ceremoniously presented the Crystal Pine Award. "Our huge thanks go to the three main organizers from the Glaser family—Marijana, Ozren, and producer Zeljko Glaser. I would like to express my appreciation for their excellent, professional organization and for building a festival of a truly Hollywood standard, where one felt like they were at the Oscars from the very first moment," concludes Vlado Zelezňák Jr.A World Premiere of Visual Poetry Before an Elite Audience The World Premiere of Angel & Meow, held on May 22 at CineStar Varazdin, played to a fully packed theater. The audience consisted of an elite group of nominated composers, sound designers, and filmmakers from around the world. The premiere was attended in person by living legends of the film industry, such as Oscar-winning sound mixer Mark Ulano (Titanic, Inglourious Basterds), as well as singer and producer Kathy Kelly from the legendary group The Kelly Family.In addition to high-quality animation and visuals, the international jury praised the film’s powerful sound design, original score, and the overall story, all created by Vlado Zelezňák Jr. The visual and animation components were crafted by a top-tier Japanese team in Tokyo, led by director and lead animator Clemhyn Escosora from Adarnia studio (a subsidiary of Fuji Corp.).Global Sound Design and a Soundtrack as a Narrator Since the story relies on the pure power of image and sound, the meticulously designed sound and film music step into the spotlight, taking on the role of the primary narrator alongside the animation. The resulting soundtrack is exceptionally rich, varied, and intense."The sound design was created all over the world. While atmospheric sounds were recorded directly on the streets and coast of Cannes, the orchestral and electronic music was composed in studios in Slovakia. To achieve absolute authenticity, we recorded live animals and constantly experimented with sound," explains Vlado Zelezňák Jr. Over the 15-minute runtime, the viewer experiences diverse musical landscapes—from massive orchestral passages and intimate piano and guitar moments to pure sci-fi sounds of analog Moog synthesizers and wind instruments.Sound in the Hands of a Living Legend The final sound mastering was handled in the USA by an absolute legend in the field—Vlado Meller, in his prestigious American studio. Throughout his rich career, he has collaborated with icons such as Céline Dion, Andrea Bocelli, and the Red Hot Chili Peppers. Meller recently exclusively finished Dolby Atmos mastering for Michael Jackson’s legendary albums for Sony USA, released in conjunction with the recently unveiled biographical film hit Michael.Angel & Meow has shown from the very start that independent Slovak production from the GONG Art Company workshop, combined with an original script, film music, and sound design, can successfully stand its ground on the international stage against the world's biggest productions.About GONG Art Company30 Years of Creativity and Innovation GONG Art Company is an established pillar of the Slovak audiovisual scene with a nearly 30-year history. The company is renowned for its long-standing technological and creative co-production work with Slovak National Television and Radio, providing comprehensive music production for iconic projects such as Hviezdička and Zlatá brána. The company has been awarded multiple Gold and Platinum records for its music production and children's audio titles.Today, GONG operates as a modern production house focused on international film co-productions. The company manages its own film projects, with in-house recording studios dedicated to film scoring and sound design. This infrastructure allows for simultaneous production across multiple works—while the soundtrack for Angel & Meow was being composed in one studio, another was handling sound post-production for the documentary Man from the Mountain, which is also heading to international film festivals this year.GONG is also the founder of the global platform FMC (Film Music Contest & Festival), which connects elites from Hollywood and Netflix with global talent. The team regularly participates in key industry markets such as Cannes (Marché du Film), Annecy (MIFA), and Berlinale (EFM), building on a tradition of high-quality original work with the ambition to succeed in the global market.More information: www.angelandmeow.com Media Contact: Mgr. Vlado Zelezňák JR. Phone: +421 911 789 888 Email: press@angelandmeow.com Facebook: https://www.facebook.com/angelandmeowmovie/ Instagram: https://www.instagram.com/angelandmeowmovie/  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA‑ASI) is deepening its footprint in the Dutch innovation ecosystem, with new investments in six Netherlands-based technology companies through its Blue Magic Netherlands (BMN) venturing initiative.These new partnerships follow the latest BMN event in Eindhoven, a fast-paced, "shark tank"-style forum in which Dutch startups and scaleups pitched breakthrough technologies directly to GA‑ASI decision makers. The most recent edition drew more than 350 attendees from across the country's aerospace, defense, and high-tech communities.Building on the success of prior events, GA‑ASI has selected six Dutch companies for new investment and collaboration. GA-ASI also is increasing its investment in Emergent Swarm, first discovered at BMN 2024. Emergent Swarm is partnering with GA‑ASI to further mature its swarming autonomy detection capability."Blue Magic Netherlands is our window into the Dutch innovation ecosystem," said Brad Lunn, Managing Director, GA‑ASI. "We are not just scouting ideas. We are deploying capital, engineering resources, and access to platforms to help these companies scale. We're making these new investments because it is clear to us that the Netherlands is one of the most dynamic technology hubs in Europe."The six new GA‑ASI portfolio companies are:OPT/NET B.V. - GA-ASI, alongside its GA-Intelligence affiliate, will be working with OPT/NET to explore collaboration opportunities for a variety of AI-related missions, including drone swarm management and dark vessel detection.Vaeridion B.V. - GA-ASI will be working with Vaeridion to evaluate their advanced battery pack technology for use in current and future GA-ASI platforms.Touchwaves B.V. - GA-ASI will be evaluating Touchwaves' haptic technology for use in remotely piloted UAS environments to determine the potential benefits to long-duration missions and aircrew information overload.FDCL Defence B.V. - GA-ASI and GA-Intelligence will be working with Fiducial to explore the effectiveness of the company's technology toward massively scaled low-cost future platforms.Vydar Commercial B.V. - GA-ASI will evaluate Vydar's technology in a variety of relevant GPS-denied environments and GA-ASI and GA-EMS platforms.Emproof B.V. - GA-ASI will evaluate the effectiveness of Emproof's data protection technology for applicability to current and future GA-ASI platforms.GA‑ASI expects to announce additional investments from the 2025 BMN cohort in the coming months, as technical evaluations and co‑development discussions progress.About Blue Magic VenturesBlue Magic Ventures is GA‑ASI's corporate venturing initiative, designed to identify, invest in, and scale breakthrough technologies from startups and innovators around the world. Through capital investment, access to platforms, and deep technical collaboration, Blue Magic Ventures accelerates the path from concept to capability for dual‑use technologies.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加州聖地牙哥, 2026年6月9日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司（GA ASI）正透過其「藍魔力荷蘭」（BMN）創投計畫，對六家總部位於荷蘭的科技公司進行新投資，藉此深化其在荷蘭創新生態系統中的佈局。這些新夥伴關係源於在埃因霍溫舉辦的最新一屆「藍魔力荷蘭」活動。該活動採用快節奏的「創投大鯊魚」風格論壇形式，讓荷蘭新創企業與成長型企業能直接向GA ASI決策者展示其突破性技術。本屆活動吸引了來自全國航空航天、國防及高科技領域的超過350名與會者。基於過往活動的成功經驗，GA ASI已選定六家荷蘭企業進行新投資與合作。GA-ASI 同時也將增加對 Emergent Swarm 的投資，該公司最初是在 2024 年 BMN 活動中被發掘的。Emergent Swarm 正與 GA ASI 合作，以進一步完善其群體自主偵測能力。「Blue Magic Netherlands 是我們窺探荷蘭創新生態系的窗口，」GA ASI 董事總經理 Brad Lunn 表示。「我們不僅在發掘創意，更投入資金、工程資源及平台管道，協助這些企業擴大規模。我們之所以進行這些新投資，是因為我們清楚地看到，荷蘭是歐洲最具活力的科技樞紐之一。」GA ASI 旗下六家新投資企業如下：OPT/NET B.V. — GA-ASI 將與旗下子公司 GA-Intelligence 攜手，與 OPT/NET 合作探索各項 AI 相關任務的合作機會，包括無人機群管理與暗色船隻偵測。Vaeridion B.V. — GA-ASI 將與 Vaeridion 合作，評估其先進電池組技術在 GA-ASI 現有及未來平台中的應用潛力。Touchwaves B.V. — GA-ASI 將評估 Touchwaves 的觸覺技術在遙控無人機系統（UAS）環境中的應用，以確定該技術對長時間任務及緩解飛行員資訊過載的潛在效益。FDCL Defence B.V. - GA-ASI 與 GA-Intelligence 將與 Fiducial 合作，探討該公司技術在未來大規模低成本平台上的有效性。Vydar Commercial B.V. - GA-ASI 將在各種相關的 GPS 受限環境中，以及 GA-ASI 與 GA-EMS 平台上評估 Vydar 的技術。Emproof B.V. - GA-ASI 將評估 Emproof 的資料保護技術，以確認其適用於現有及未來的 GA-ASI 平台。隨著技術評估與共同開發討論的推進，GA-ASI 預計將於未來數月內宣布 2025 年 BMN 投資組的更多投資項目。關於 Blue Magic VenturesBlue Magic Ventures 是 GA-ASI 的企業創投計畫，旨在發掘、投資並擴展來自全球新創公司與創新者的突破性技術。透過資本投資、平台資源及深度技術合作，Blue Magic Ventures 加速雙用技術從概念到實用能力的發展進程。關於 GA-ASI通用原子航空系統公司（General Atomics Aeronautical Systems, Inc.）是全球首屈一指的無人機系統（UAS）製造商。「捕食者®」（Predator®）系列無人機系統累積飛行時數已超過 900 萬小時，服役逾 30 年，包含 MQ-9A「死神®」（Reaper®）、MQ-1C「灰鷹®」（Gray Eagle®）、MQ-20「復仇者®」（Avenger®）以及 MQ-9B「天衛®」（SkyGuardian®）/「海衛®」（SeaGuardian®）。該公司致力於提供長航時、多任務解決方案，以實現持續的戰場態勢感知與快速打擊能力。欲了解更多資訊，請造訪 www.ga-asi.com 。Avenger、EagleEye、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 及 SkyGuardian 均為通用原子航空系統公司（General Atomics Aeronautical Systems, Inc.）於美國及／或其他國家註冊的商標。GA-ASI 媒體關係通用原子航空系統公司ASI-MediaRelations@ga-asi.com (858) 524-8101消息來源：通用原子航空系統公司 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HO CHI MINH / SEOUL, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Global content-tech company TON Corporation (CEO Henry Kim) today announced that it will officially launch 'TonTV', its Telegram-native short-drama platform, worldwide in September 2026. TonTV lets the ~1 billion people who use Telegram each month instantly and freely watch short dramas with a single Telegram account — with no separate app install and no complicated sign-up.Short drama is one of entertainment's fastest-rising categoriesShort-form drama has moved to the center of global media consumption. Global in-app revenue for short dramas reached $2.98 billion in 2025, up 115% year over year, and in Q4 2025 short-form titles overtook long-form streaming apps in downloads for the first time (733M vs. 658M), according to Sensor Tower and Omdia. With short runtimes, high completion rates, and mobile-first immersion, the format is growing fastest among younger viewers. TonTV places dramas of around two minutes at the heart of this trend — short but intense chapters that build a "can't-stop-once-you-start" experience.The Telegram Mini App: tearing down the barrier to entryTonTV's core strength is that it runs atop Telegram, a massive global platform. Existing OTT services require a long entry sequence — app-store search → download → install → sign-up → enter payment details. TonTV removes it: open the Mini App inside Telegram → watch instantly, for free.The user reach that global OTT leaders such as Netflix and Disney+ built over years and at enormous cost is something TonTV can address from day one, across Telegram's ~1 billion monthly users. This dramatically lowers user-acquisition cost while driving early growth through natural word-of-mouth across Telegram's groups and channels.Three years of preparation, and "why we can win"TonTV did not appear overnight. Over the past three years, TON Corporation has focused on platform-technology development, global content partnerships, and a local-operations model in preparation for launch.CTO Tony cited the following reasons TonTV can be a market "game changer" rather than a late follower:Frictionless reach — among the first specialized short-drama platforms to reach Telegram's ~1 billion monthly users, free, in one clickFree entry — anyone can start at no cost, a strong advantage for early user acquisitionNetwork effects — discussion, sharing, and recommendation happen at the same moment as viewingViewer-participation rewards — enjoying content itself returns benefits and rewards, building loyaltySimultaneous global release — worldwide at once, with no region-by-region app-store approvalOn these strengths, TonTV aims to grow beyond short drama into real-time formats such as live streaming over time.A 'new stage' for producers, actors, and staff worldwideTonTV goes beyond a viewing platform to open opportunity for the global content industry. Producers can showcase work directly to a global audience; actors and staff can widen their stage across borders. For emerging teams and new actors who have struggled to get a chance at traditional broadcasters or large OTTs, TonTV offers an open stage judged on ability — creating jobs across planning, production, acting, and post-production."Global one platform, local content"TonTV places local subsidiaries in major markets — Korea, Japan, Vietnam, India, Indonesia, and the Philippines — planning and producing content suited to each region's culture on the ground. Combining a global platform's scale with local content's intimacy, TonTV aims to be a true global OTT where anyone can enjoy "stories from home." The local-subsidiary model expands content and markets quickly while keeping head-office cost low.A dual revenue model: "growth and profit together"TonTV operates a dual model: a free, ad-supported tier where all users watch at no cost, and a premium subscription for an ad-free experience. Advertiser acquisition and content production through local subsidiaries create a cycle in which ad and subscription revenue grow with the user base. Telegram's low acquisition cost and short-form's high completion rates support this model.Comment from TON Corporation CTO TonyCTO Tony said: "For the past three years we've focused everything on creating the easiest, most enjoyable way to watch drama. On Telegram — a playground of a billion people — TonTV sets a new standard for short drama anyone can enjoy free, with a single account."He added: "TonTV will create the best experience for viewers, a new stage for creators, and new jobs for the industry — and our ambition is to become the global leader in short-drama and live content."Future plansFrom its September 2026 launch, TonTV plans to rapidly expand its content lineup and service regions, broaden from short drama into real-time formats such as live streaming, and accelerate global expansion through its local subsidiaries.About TON CorporationTON Corporation is a global content-tech company headquartered in Ho Chi Minh, Vietnam. Through TonTV, its Telegram-native short-drama platform, it aims to deliver a new entertainment experience to users worldwide and open opportunity for global content creators.Media ContactBrand: TON CorporationContact: PR TeamWebsite: https://tontv.toncorp.ioTelegram: https://t.me/TontvOfficialChannel Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008"), have been presented in a poster at the American Diabetes Association (ADA) 86th Scientific Sessions (June 5-8, 2026, New Orleans, USA). As the world's largest and most authoritative annual scientific meeting in the fields of diabetes and metabolic diseases, it convened over 12,000 leading clinicians, researchers, and healthcare professionals worldwide to explore cutting-edge advances in diagnostics, therapies, and technologies.About CMS-D008CMS-D008 is a self-developed novel siRNA therapy administered by subcutaneous injection. It targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of INHBE-encoded Activin E protein, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. It demonstrates the potential for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. Currently, the Phase I clinical trial of CMS-D008 in healthy subjects is progressing steadily. In the future, it may be developed for the treatment of abdominal obesity and related metabolic diseases.CMS-D008 has demonstrated encouraging preclinical data. The preclinical research results of CMS-D008 presented at the ADA Scientific Sessions showed that in obese animal models, CMS-D008 efficiently and sustainably suppressed INHBE expression, achieving significant weight loss and fat reduction while sparing muscle mass, with a favorable safety profile, indicating the potential for healthy weight loss. Details are as follows:Title: CMS-D008 specifically silences INHBE mRNA, delivering fat-selective weight loss in preclinical studyPresentation Number: 3079-LBPresentation format: PosterDate/Time: June 7, 2026 01:30 PM - 02:30 PM (Local Time)Location: Hall D-EResults:In a high-fat diet-induced model of humanized INHBE obese mouse (hINHBE DIO mouse), CMS-D008 significantly reduced hepatic INHBE mRNA expression and serum Activin E protein levels, leading to marked decreases in body weight, total body fat, and regional fat mass while preserving lean mass.In a model of obese cynomolgus macaque, CMS-D008 also significantly reduced hepatic INHBE mRNA expression and plasma Activin E protein levels, and effectively suppressed weight gain induced by a sustained high-fat diet.The inclusion of these findings at the ADA Scientific Sessions reflects the international academic community's interest in the scientific value and clinical potential of CMS-D008 in the field of obesity/metabolic treatment. CMS-D008 will synergize with CMS-D005, a self-developed, clinical-stage innovative drug (a GLP-1R/GCGR dual agonist), to deliver highly effective weight-loss benefits and long-term maintenance of results, providing patients with a more comprehensive and innovative treatment option.CMS is committed to in-house R&D as a core driver of its long-term growth and continues to advance innovation in cutting-edge therapeutic areas. Currently, 6 self-developed products with global rights, including CMS-D008, have entered the clinical stage, with over 20 additional self-developed projects steadily progressing in preclinical research. Looking ahead, the Group will continue to focus on unmet medical needs, efficiently advance product R&D and commercialization, and bring more comprehensive and innovative therapies to benefit broad patient population.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年6月8日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀（HKEX 1952.HK）宣佈與箕星藥業（以下簡稱「箕星」）達成資產收購協議 (The Asset Purchase Agreement)，獲得LNZ100（1.44% 醋克利定，美國商品名VIZZ）在大中華區（包含中國大陸，中國香港，中國澳門和中國台灣地區）的開發、生產與商業化權益。根據協議，雲頂新耀將向箕星藥業支付首付款以及開發里程碑付款。作為本協議的一部分，雲頂新耀將獲得箕星藥業於2022年4月簽訂的許可協議及相關附屬協議項下的權利、權益、主張、職責、義務及責任。此次交易將進一步豐富公司的創新產品組合，強化雲頂新耀在眼科領域的佈局，並提升戰略協同效應。LNZ100是一款每日滴用一次、用於治療老視的滴眼液，其主要成分醋克利定是一種小分子毒蕈堿型乙醯膽鹼能受體（mAChR）激動劑，可引起瞳孔縮小，從而產生改善近視力的針孔效應。研究表明醋克利定的作用機制非常理想，基於其獨特的高選擇性瞳孔作用機制，既可以產生理想的縮瞳效應，又避免了近視漂移，因此具有針對最廣泛患者群體的應用潛力。據公開資料顯示，LNZ100已於2025年7月在美國獲批，並於同年10月實現商業化上市；在中國，LNZ100已於2025年9月遞交新藥上市申請，預計2027年第一季度獲批，有望填補國內治療空白，成為針對老視的潛在同類最佳無創治療方案。雲頂新耀董事會主席吳以芳表示：「此次收購LNZ100是公司持續深化眼科領域戰略佈局的重要一步。LNZ100作為一款兼具差異化優勢和廣闊市場前景的創新產品，在老視治療領域具有明確的臨床價值與應用潛力。隨著人口結構變化，老視患者群體不斷擴大，而無創治療仍存在顯著未滿足的需求。LNZ100有望為老視患者提供全新的治療選擇，並進一步豐富眼科創新治療方案。 LNZ100已在美國獲批上市，目前正在中國加快推進新藥上市審評進程。未來，我們將加快LNZ100的開發和上市，推動這一創新療法儘早惠及更多老視患者。」箕星藥業董事會執行董事兼首席執行官牟豔萍表示：「我們相信雲頂新耀憑藉其卓越的商業化能力，將加速推進LNZ100的市場可及性，惠及更多中國老視患者。此次交易之後，箕星的產品管線全部聚焦心血管及代謝疾病治療領域，該交易所獲資金將助力箕星加速推進創新管線的全球臨床開發。」老視，俗稱「老花眼」，是指隨著年齡增長，看近處物體逐漸模糊的生理現象。其原因在於眼部晶狀體逐漸硬化、彈性減弱，導致調節功能下降，無法將近處物體的像聚焦在視網膜上，從而導致近視力下降。老視是隨年齡增長常見的生理變化，研究顯示，中國人群老視的平均發病年齡約為38歲，而到52歲時，發病率接近100%。目前，老視的治療手段非常有限。佩戴眼鏡需要頻繁摘戴，給工作和生活帶來諸多不便；手術作為侵入性、不可逆的有創操作，接受程度也十分有限。在非侵入性、安全有效且可逆的藥物治療方面，老視領域存在巨大的未滿足醫療需求。此次LNZ100獲中國NMPA新藥上市申請受理是基於中國III期臨床研究所取得的數據結果。該研究是一項多中心、隨機、雙盲、安慰劑對照的3期臨床試驗，由4周療效試驗和總計6個月的安全性試驗組成，共招募了300名受試者，旨在觀察LNZ100改善中國老視人群近視力並確證其療效與安全性。研究結果顯示，LNZ100達到了主要終點和關鍵次要終點，最佳遠矯正下的近視力 （BCDVA）有三行或更佳的顯著改善，並保持其最佳遠視力（即視力下降不可超過5個字母）。研究結果還顯示（所有p值均小於0.0001），LNZ100起效迅速，分別有84%和69%的受試者在用藥後30分鐘即獲得兩行及三行字母或更佳的近視力改善。且LNZ100藥效持久，分別有61%和30%的受試者在用藥後10 小時仍保持兩行及三行字母或更佳的近視力改善。此外，LNZ100也具備出色的安全性，耐受性良好，在試驗中沒有發現與治療相關的嚴重不良事件。近年來，雲頂新耀已建立經過驗證的以「科學及商業洞察驅動的准入、醫學、市場、銷售一體化協同（A2MS）」為核心的創新藥商業化運營平台。隨著多個創新產品陸續進入商業化階段，公司商業化平台的規模效應和協同效應正持續釋放。在此背景下，引入具備明確臨床價值和市場潛力的後期資產，成為公司豐富產品組合、拓展增長空間的重要舉措。此次獲得LNZ100大中華區權益，將進一步強化雲頂新耀眼科領域佈局，並與現有商業化體系形成協同，持續提升創新資產的商業化價值。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 8, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement, Everest has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan region. Everest will pay an upfront payment and potential development milestone payments. As part of this agreement, Everest will be assigned and transferred the rights and obligations under the LENZ License Agreement entered into by CORXEL in April 2022 and certain related ancillary agreements. This transaction is expected to further expand the Company’s innovative product portfolio, strengthen its presence in ophthalmology, and enhance overall strategic synergies across its business.LNZ100 is a once-daily prescription eye drop indicated for the treatment of presbyopia. Its active ingredient, aceclidine, is a small molecule acetylcholine receptor agonist that causes pupil contraction, or miosis, creating a pinhole effect that improves near vision. Studies have shown that aceclidine's mechanism of action (MOA) is well positioned to create a pinhole pupil effect while avoiding the impairment of distance vision called myopic shift. Aceclidine's unique pupil selective MOA, in which miosis is decoupled from myopic shift, is expected to allow it to target a broad patient population.According to publicly available information, LNZ100 received approval in the United States in July 2025 and was commercially launched in October of the same year. In China, the New Drug Application (NDA) for LNZ100 was submitted in September 2025, with approval expected in the first quarter of 2027. The therapy has the potential to address a significant unmet medical need in China and position itself as a best-in-class, non-invasive treatment option for presbyopia.“The acquisition of LNZ100 represents an important step in advancing Everest’s strategic focus in ophthalmology. LNZ100 is a differentiated asset with meaningful clinical value and strong commercial potential in the treatment of presbyopia,” said Yifang Wu, Chairman of the Board of Everest Medicines. “As the presbyopia patient population continues to grow, significant unmet needs remain in non-invasive treatment options. We believe LNZ100 has the potential to offer patients a novel, non-invasive therapeutic option and to further broaden the landscape of innovative ophthalmic treatments. The product has already been approved in the United States and is currently under regulatory review in China. We will continue to advance its development and commercialization to make this therapy accessible to presbyopia patients.”Ms. Sandy Mou, Board Executive Director and Chief Executive Officer of CORXEL, said: “We are confident that Everest Medicines’ strong commercialization capabilities will accelerate LNZ100’s market access and bring this innovative treatment to more presbyopia patients in China. Following this transaction, CORXEL’s pipeline will be entirely focused on cardiometabolic therapies. The proceeds from the transaction will enable CORXEL to accelerate the global clinical development of its innovative cardiometabolic pipeline.”Presbyopia is a physiological phenomenon associated with aging that results in a progressively worsening ability to see nearby objects clearly. It is caused by the gradual hardening of the lens. This results in a decline of the eye’s adjustment function, and the inability to focus the image of nearby objects on the retina, leading to a decline in near vision. Studies have shown that the onset of presbyopia typically occurs around the age of 38, reaching a prevalence rate of nearly 100 percent at the age of 52 in China. Currently, the treatment options for presbyopia are very limited. Wearing glasses requires frequent removal and insertion, causing many inconveniences in work and life. Surgery, as an irreversible and invasive operation, has very limited acceptance. There are no approved drugs for the treatment of presbyopia in China and the medical need for non-invasive, safe, efficient and reversible treatments for presbyopia remains unsolved.The NDA acceptance of LNZ100 by the National Medical Products Administration (NMPA) of the People’s Republic of China is based on the data from China Phase 3 Trial. The study was a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study, including a 4-week efficacy study followed by a 6-month extension safety study, designed to evaluate the efficacy and safety of LNZ100 (an aceclidine-based ophthalmic solution) in participants with presbyopia. The objectives were to assess the potential of LNZ100 to improve near vision among Chinese presbyopia patients and to evaluate the efficacy and safety profiles. The trial has enrolled 300 participants.The results showed that LNZ100 achieved the primary endpoint and key secondary endpoints, with statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near, and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). Results also showed (all p<0.0001) a rapid onset of action, with 84% and 69% of participants achieving two-line and three-line or greater improvements, respectively, within 30 minutes of administration. The effect was also durable, with 61% and 30% of participants continuing to achieve two-line and three-line or greater improvements, respectively, at 10 hours. In addition, LNZ100 was well tolerated, and no serious treatment-related adverse events were observed in the trial.In recent years, Everest has built a proven platform for the commercialization of innovative medicines, integrating scientific and commercial insights with coordinated access, medical, marketing, and sales (A2MS). As multiple innovative products have entered the commercialization stage, the platform’s scale and synergy effects continue to strengthen. Against this backdrop, the acquisition of late-stage assets with clear clinical value and commercial potential has become an important approach for Everest to enrich its product portfolio and expand future growth opportunities. The acquisition of Greater China rights to LNZ100 further strengthens Everest Medicines’ presence in the ophthalmology and is expected to generate synergies with its existing commercialization infrastructure, supporting the continued realization of the asset’s commercial value. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年6月8日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（867.HK/8A8.SG）（「康哲藥業」）欣然宣佈，其自主研發的創新藥INHBE小核酸藥物CMS-D008注射液（「CMS-D008」）的臨床前結果在第86屆美國糖尿病協會（ADA）大會（2026年6月5-8日，美國新奧爾良）以壁報形式發佈。ADA大會作為全球糖尿病及代謝疾病領域規模最大、最具權威影響力的年度學術風向標，此次匯聚了來自世界各地的超過12,000名頂尖臨床專家、科研學者及一線醫療工作者，共同探討與見證前沿診療成果與技術創新突破。關於CMS-D008CMS-D008是康哲藥業自主研發的一款皮下注射的siRNA藥物，靶向抑制肝臟的抑制素亞基βE（INHBE）基因表達，下調INHBE編碼蛋白激活素E（Activin E）水平，從而降低脂肪代謝通路Activin E-ALK7的活化，有效減少脂質堆積，顯示出減脂不減肌、長期高質量減重的潛力。目前，CMS-D008的健康受試者I期臨床試驗正在穩步推進中；未來擬開發治療腹型肥胖以及相關代謝性疾病。CMS-D008展現出令人鼓舞的非臨床數據。本次在ADA大會發表CMS-D008的臨床前研究結果顯示，在肥胖動物模型中，CMS-D008可高效持續抑制INHBE表達，在不影響肌肉的情況下，獲得明顯的減重減脂效果，且安全性良好，有望實現健康減重。具體信息如下：標題：CMS-D008可特異性抑制INHBE mRNA，並在臨床前研究中實現了針對脂肪的減重效果摘要號：3079-LB展示形式：壁報時間：2026年6月7日01:30 PM - 02:30 PM（當地時間）地點：Hall D-E研究結果：- 在高脂飲食誘導的人源化INHBE肥胖小鼠（hINHBE DIO 小鼠）模型中，CMS-D008可顯著降低肝臟中INHBE mRNA及血清中靶蛋白Activin E的水準，進而顯著降低小鼠的體重、體脂、不同部位脂肪，且不影響小鼠的肌肉含量。- 在肥胖食蟹猴模型中，CMS-D008也可顯著降低肝臟中INHBE mRNA及血漿中靶蛋白Activin E的表達，並顯著抑制因持續攝入高脂飲食而引起的體重上升。此次研究成果入選ADA大會，體現了CMS-D008在肥胖/代謝治療領域的科學價值與臨床潛力受到國際學術界的關注。CMS-D008亦可與康哲藥業臨床開發階段的自研創新藥CMS-D005（GLP-1R/GCGR雙重激動劑）形成協同，有望實現高效的減重獲益與長期的成果維持，為患者提供更全面的治療方案。康哲藥業將自主研發作為長期發展的核心驅動力，持續深耕前沿創新領域。目前已有包括CMS-D008在內的6款擁有全球權益的自研產品進入臨床階段，另有逾20項自研專案穩步推進臨床前研究。未來，康哲藥業將繼續聚焦未被滿足的臨床需求，高效推動產品的研發與商業化進程，以更全面、創新的療法惠及廣大患者。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想了解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

OTTAWA, ON, June 8, 2026 - (ACN Newswire via SeaPRwire.com) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the. Air Quality Assessment ("AQA" or the "Study") for its 100%-owned Lac Knife Graphite Project (the "Project") located in northeastern Quebec.The Study was completed by WSP Canada Inc. ("WSP"), one of the world's leading engineering and environmental consulting firms, under the supervision and management of IOS Geosciences Inc. ("IOS"), as part of the environmental studies supporting the advancement of Lac Knife toward future permitting and development.The AQA evaluated emissions associated with the proposed open pit mine, processing facility, tailings storage facility, stockpiles, haul roads, crushing operations, and supporting infrastructure under conservative maximum operating scenarios. Atmospheric dispersion modelling using Aeromod software, was completed in accordance with the requirements of Quebec's Reglement sur l'assainissement de l'atmosphere ("RAA") and applicable guidance from the Ministere de l'Environnement, de la Lutte contre les changements climatiques, de la Faune et des Parcs ("MELCCFP").According to WSP's conclusions, the modelling results demonstrate that predicted contaminant concentrations remain in compliance with applicable Quebec ambient air quality standards and criteria under the assessed operating conditions. WSP further concluded that all evaluated contaminants met applicable regulatory thresholds. The Study also noted that prevailing winds are predominantly directed toward the south-southeast, away from nearby public infrastructure, residences, and seasonal fishing cabins."Environmental permitting is one of the most important value-creation stages in the development of any critical mineral project," said Dean Hanisch, CEO of Focus Graphite. "The completion of the Air Quality Assessment represents another key component of the broader environmental review process and brings us closer to completing the environmental studies required to support future permitting activities. As these workstreams are completed, Lac Knife continues to become increasingly de-risked from both a technical and environmental perspective while strengthening its position as a strategic North American graphite asset."The Study evaluated a broad range of potential emissions, including particulate matter, nitrogen oxides, sulphur dioxide, carbon monoxide, crystalline silica, and various metals, using a detailed atmospheric dispersion model of the Project area and surrounding receptors based on five years of regional meteorological data.Advancing Toward Environmental Assessment CompletionThe AQA forms part of the broader environmental and permitting work program being advanced at Lac Knife and represents another important milestone toward completion of the environmental and social impact assessment ("ESIA") process. With this Study now complete, the Company is advancing the remaining key environmental workstreams, including the hydrogeological assessment and dam breach analysis, which are expected to further support permitting activities and future project development.The completion of the AQA builds on a series of technical, environmental and infrastructure achievements that continue to de-risk the Project and strengthen Lac Knife's position as a strategically important North American graphite asset. As demand for secure and reliable graphite supply continues to grow, Focus remains focused on advancing the Project through the key milestones required for future development.Qualified PersonThe technical content disclosed in this news release was reviewed and approved by Rejean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals — reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc., please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things: the advancement of the Lac Knife Graphite Project toward permitting readiness and future development; the completion and timing of the remaining environmental studies required to support the environmental and social impact assessment ("ESIA") process, including the hydrogeological assessment and dam breach analysis; the anticipated completion of environmental baseline, technical and permitting workstreams; the Company's ability to obtain required permits, approvals and authorizations; the anticipated benefits of completed environmental and technical studies, including the Air Quality Assessment; the timing and completion of future project milestones; the future development, construction and operation of the Lac Knife Project; the role of the Project in supporting North American and allied critical mineral supply chains; and the Company's long-term development strategy.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300471 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 7, 2026 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) will host a "Hong Kong Tech Pavilion" at Viva Technology (VivaTech) 2026, Europe’s premier annual startup and technology summit in Paris, from next Wednesday, 17 to Saturday, 20 June. In collaboration with our strategic partner, the Hong Kong Economic and Trade Office in Brussels, the Pavilion will bring together 24 Hong Kong startups to showcase innovations in artificial intelligence and robotics, health technology, and sustainability and climate technology. A series of thematic seminars, startup pitching sessions, and networking receptions will also be held to facilitate exchanges between global investors, buyers, and Hong Kong startups, fostering international collaboration. Several key partners, including Hong Kong Science and Technology Parks Corporation, Hong Kong Polytechnic University, Hong Kong Productivity Council, Hong Kong University of Science and Technology, and Cyberport, support the initiative.HKTDC’s Chris Lo, Regional Director, Europe, Central Asia & Israel, stated: "Hong Kong is actively developing into an international innovation and technology hub. As one of the key enablers, the HKTDC supports enterprises in going global by curating overseas platforms and facilitating cross-regional exchanges. Building on last year's success, we are further expanding the Hong Kong Tech Pavilion at VivaTech this year to deepen connections among startups, tech leaders, large corporations, and investors, fostering innovative collaborations and business matchmaking, assisting innovation and technology enterprises in exploring overseas markets, and showcasing to Europe Hong Kong's unique advantages as an international innovation hub."During the exhibition, the HKTDC will organise a series of events, including thematic seminars, startup pitching sessions, and networking activities, to explore future development trends for Hong Kong startups and global collaboration opportunities.Shirley Yung, Special Representative for Hong Kong Economic & Trade Affairs to the European Union, will attend and deliver a keynote speech at the thematic seminar and networking reception titled "Building Resilient Tech Ecosystems: Powering the Next Wave of International Tech Leadership from Hong Kong" on 19 June. The seminar will feature three main segments: "Launching from Hong Kong: The Innovation Infrastructure Powering Start-up Breakthrough”, where Hong Kong Science and Technology Parks Corporation, and startups will share local success stories; "Engineering for Success: How Hong Kong’s Innovation Landscape Helps Tech Companies Achieve Market Fit'”, featuring Hong Kong Productivity Council and enterprise representatives exploring market matchmaking; and a concluding panel discussion inviting representatives from academia, incubators and technology institutions to examine how talent and infrastructure drive Hong Kong's technological development and international collaboration.Helping Hong Kong startups pitch to global investorsParticipating startups at VivaTech’s Hong Kong Tech Pavilion will showcase their innovative solutions and products to investors from around the world. Three thematic pitching sessions will be held over the first three days:17 June (afternoon): Robotics and Microelectronics theme, featuring seven enterprises showcasing their innovative achievements including Bacbudy Limited, which develops intelligent wearable and robotic assistive devices for the lower back, and Cybercrystal Technology Co., which researches next-generation robotic optical tactile skin.18 June (morning): Artificial Intelligence and Health Technology theme, featuring eight enterprises presenting breakthrough innovations in AI and health technology including Eieling Technology, which develops portable chronic liver disease medical diagnostics and AI applications, and Point Fit Technology, which develops wearable health monitoring and intelligent sports solutions.19 June (noon): Sustainability and Climate Technology theme, featuring seven enterprises including Albacastor Technology, which develops eco-friendly industrial oil-removal and deodorising ventilation systems, and Green Vigor, which develops energy recovery and green power generation technologies.Additional events include: On the first day (17 June), the thematic seminar "Europe to Hong Kong: Building a Startup Between Two Ecosystems" will be moderated by Christopher Lai, Director, France, Spain & Portugal of HKTDC, inviting French entrepreneurs to share their experiences in business expansion across Europe and Hong Kong, analysing the differences between the two ecosystems, and exploring how to leverage Hong Kong as a platform for entering the Asian market and securing funding.On the exhibition’s second day (18 June), Hong Kong Science and Technology Parks Corporation will host the "HKSTP Global Mixer: Inside Hong Kong’s Startup Acceleration Playbook", exploring how Hong Kong connects with the global innovation and technology ecosystem and its advantages in talent and investment. In the same afternoon, Hong Kong Polytechnic University will host the “Breaking Barriers with Autonomous Systems: Transforming Industries with AI Innovation”, showcasing Hong Kong’s unique position in harnessing the power of AI and its world-class academia to develop a globally leading innovation hub. That evening, the "Hong Kong Tech Night: Where Innovation Meets Opportunity" networking event will bring together the innovation and technology communities of Hong Kong and France, fostering collaboration between both sides in talent, funding, and market expansion.The VivaTech 2026 Hong Kong Tech Pavilion is located at Booth 1C11, Hall 7.1, Paris Expo Porte de Versailles. The 10th edition of VivaTech is expected to attract more than 180,000 visitors, 14,000 global startups, and 3,600 investors, bringing together industry leaders from around the world to become a key focal point of the international innovation and technology ecosystem.VivaTech Hong Kong Tech Pavilion is an Economic and Trade Express flagship event, which helps Hong Kong SMEs and startups explore overseas market opportunities while attracting more companies to invest and establish operations in Hong Kong.List of 24 Start-ups at the Hong Kong Tech Pavilion: CategoryCompany Name1.     Sustainable & Climate TechnologyAlbacastor Technology Limited2.     AIGreen Limited 3.     Asgard Group Limited 4.     Formwork IO5.     Green Vigor Limited6.     Laputa Eco-Construction Material Company Limited7.     LeafIoT Technology Limited8.     Plasticvore Chain Ltd 9.     AI and Software Solutions Cogniser Infotech Ltd10.  D-Engraver Limited11.  Midas Analytics Limited 12.  OxGen Holdings Limited13.  Pantheon Lab Limited14.  SagaDigits Limited15.  Robotics and Microelectronics TechnologyAnlaseo Technology Limited16.  Bacbudy Limited17.  Cybercrystal Technology Co., Limited18.  Harmony SkyTech Limited19.  Oriental Materials Hong Kong Limited20.  Robocore Technology Limited21.  Health TechnologyEieling Technology Limited22.  Hong Kong Bionic Beet Robotics Limited23.  Point Fit Technology Limited 24.  UniversityThe Hong Kong Polytechnic UniversityPhoto download: https://bit.ly/3RxuMDZThe HKTDC will host the Hong Kong Tech Pavilion at VivaTech 2026. The picture shows last year’s pavilion.  During VivaTech, the HKTDC will host a series of exciting events including thematic seminars, startup pitching sessions, and networking receptions, and will arrange business matchmaking with representatives from various enterprises and organisations to assist startups in exploring the European market.Websites: https://vivatech.com/exhibitors/hktdc-hong-kong-trade-development-councilMedia enquiriesFor enquiries, please contact HKTDC’s Communications & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com